BEY1107

Phase 1Small molecule

BBeyondBio Inc.

BEY1107 is one of 110 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

109

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Glioblastoma MultiformeActive, not recruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Glioblastoma MultiformePhase 1

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

108 2

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 3

ABI-007

Bristol-Myers Squibb

Preclinical

2 4

Chemotherapy Agents

Takeda

Preclinical

1 5

Active Comparator

Moderna

Preclinical

1 6

LDE225

Novartis

Preclinical

1 7

Thiazolidinediones

Sanofi

Preclinical

1 8

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 9

Meglitinides

Sanofi

Preclinical

1 10

Secretin-Ferring

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Glioblastoma Multiforme

NCT05769660

Phase 1/2Recruiting

Metastatic Colorectal Cancer

NCT05093907

Phase 1/2Recruiting

Pancreatic Cancer

NCT03579836

Clinical

Trials by Indication[1]

Glioblastoma Multiforme1 trial

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)

Recruiting·BBeyondBio Inc.·Phase 1·NCT05769660·12 enrolled

Metastatic Colorectal Cancer1 trial

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer

Recruiting·BBeyondBio Inc.·Phase 1/2·NCT05093907·27 enrolled

Pancreatic Cancer1 trial

Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

Recruiting·BBeyondBio Inc.·Phase 1/2·NCT03579836·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BEY1107. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BEY1107 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BEY1107. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeyondBio Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBeyondBio Inc.

BEY1107

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Glioblastoma Multiforme1 trial

Metastatic Colorectal Cancer1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News